In the second of his three-part Pharmaceutical Commerce interview, Jay Bregman discusses how rising demand for GLP-1 therapies is challenging employers to reassess how they manage ...

In today's Pharma Pulse, ongoing conflict in the Middle East disrupts critical pharmaceutical cold chains, while AstraZeneca and partners launch a new program to decarbonize industrial heat across ...

Ongoing conflict in the Middle East has pushed pharmaceutical companies into cold chain rerouting scrambles. Conflict in the Middle East is disrupting pharmaceutical supply chains, as the closure and ...

For those managing pharmaceutical supply chains, the transition to low-carbon heat is no longer elective. Evolving regulatory frameworks, such as the European Union’s Carbon Border Adjustment ...

In today’s Pharma Pulse, the FDA expands a key biologic approval for pediatric patients, and new research highlights the success of pharmacist-led testing in rural communities.

Kroger’s retail rollout shifts Zepbound KwikPen distribution from direct-to-consumer to community pharmacy channels, potentially reducing friction in initiation and refills for GLP-1 obesity therapy.

Orphan drugs are forecast to surpass $400 billion in 2032 sales, driven by accelerating rare disease innovation despite regulatory volatility, pricing pressures, and capital competition from ...

SteinCares and Shilpa Biologicals have entered a licensing agreement to commercialize biosimilars in Latin America. Under the deal, SteinCares will manage regional registration and distribution, while ...

A $3 billion China investment targets localized oral solid-dose manufacturing and supply-chain redundancy to support ...

Data provided by BackOps indicates significant performance gains for early adopters across various industries, including retail, grocery, and manufacturing. The platform reportedly accelerates ...